$CDNA
CareDx, Inc.

2018 Q2 Form 10-Q Financial Statement

#000156459018021123 Filed on August 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2
Revenue $17.82M $12.05M
YoY Change 47.96% 12.21%
Cost Of Revenue $7.207M $5.190M
YoY Change 38.86% 81.98%
Gross Profit $10.62M $6.860M
YoY Change 54.75% -12.98%
Gross Profit Margin 59.56% 56.95%
Selling, General & Admin $11.46M $7.400M
YoY Change 54.86% -15.42%
% of Gross Profit 107.95% 107.87%
Research & Development $3.496M $3.120M
YoY Change 12.05% -0.73%
% of Gross Profit 32.93% 45.48%
Depreciation & Amortization $990.0K $890.0K
YoY Change 11.24% 5.95%
% of Gross Profit 9.33% 12.97%
Operating Expenses $15.83M $15.65M
YoY Change 1.15% -11.63%
Operating Profit -$5.209M -$3.599M
YoY Change 44.73% -48.35%
Interest Expense -$424.0K -$1.691M
YoY Change -74.93% -421.48%
% of Operating Profit
Other Income/Expense, Net -$9.234M -$188.0K
YoY Change 4811.7% -31.39%
Pretax Income -$14.44M -$4.411M
YoY Change 227.43% -59.65%
Income Tax -$381.0K -$376.0K
% Of Pretax Income
Net Earnings -$14.06M -$3.968M
YoY Change 254.39% -62.1%
Net Earnings / Revenue -78.9% -32.94%
Basic Earnings Per Share -$0.40 -$0.19
Diluted Earnings Per Share -$0.40 -$0.19
COMMON SHARES
Basic Shares Outstanding 35.55M shares 21.41M
Diluted Shares Outstanding 35.55M shares 21.41M

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.20M $9.100M
YoY Change 78.02% -46.78%
Cash & Equivalents $16.25M $18.66M
Short-Term Investments
Other Short-Term Assets $1.600M $1.500M
YoY Change 6.67% -16.67%
Inventory $4.666M $6.300M
Prepaid Expenses
Receivables $8.072M $3.000M
Other Receivables $0.00 $0.00
Total Short-Term Assets $30.58M $19.90M
YoY Change 53.65% -38.77%
LONG-TERM ASSETS
Property, Plant & Equipment $2.360M $2.500M
YoY Change -5.6% -26.47%
Goodwill $12.01M
YoY Change
Intangibles $34.76M
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $9.600M
YoY Change -97.92% 4700.0%
Total Long-Term Assets $49.30M $57.84M
YoY Change -14.76% -14.89%
TOTAL ASSETS
Total Short-Term Assets $30.58M $19.90M
Total Long-Term Assets $49.30M $57.84M
Total Assets $79.88M $77.74M
YoY Change 2.75% -22.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.480M $3.600M
YoY Change -3.33% 9.09%
Accrued Expenses $6.700M $8.700M
YoY Change -22.99% -20.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $33.90M
YoY Change -100.0% 87.29%
Total Short-Term Liabilities $14.18M $54.20M
YoY Change -73.85% 41.88%
LONG-TERM LIABILITIES
Long-Term Debt $13.34M $0.00
YoY Change -100.0%
Other Long-Term Liabilities $19.70M $1.349M
YoY Change 1360.34% -88.66%
Total Long-Term Liabilities $13.34M $1.349M
YoY Change 888.66% -86.61%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.18M $54.20M
Total Long-Term Liabilities $13.34M $1.349M
Total Liabilities $27.51M $65.75M
YoY Change -58.16% -4.15%
SHAREHOLDERS EQUITY
Retained Earnings -$288.1M -$222.1M
YoY Change 29.74%
Common Stock $321.1M $236.6M
YoY Change 35.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $28.95M $11.83M
YoY Change
Total Liabilities & Shareholders Equity $79.88M $77.74M
YoY Change 2.75% -22.65%

Cashflow Statement

Concept 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$14.06M -$3.968M
YoY Change 254.39% -62.1%
Depreciation, Depletion And Amortization $990.0K $890.0K
YoY Change 11.24% 5.95%
Cash From Operating Activities -$1.880M -$3.200M
YoY Change -41.25% -47.28%
INVESTING ACTIVITIES
Capital Expenditures -$5.600M -$20.00K
YoY Change 27900.0% -88.24%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$5.610M -$20.00K
YoY Change 27950.0% -99.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.080M 220.0K
YoY Change 2209.09% -98.91%
NET CHANGE
Cash From Operating Activities -1.880M -3.200M
Cash From Investing Activities -5.610M -20.00K
Cash From Financing Activities 5.080M 220.0K
Net Change In Cash -2.410M -3.000M
YoY Change -19.67% -54.48%
FREE CASH FLOW
Cash From Operating Activities -$1.880M -$3.200M
Capital Expenditures -$5.600M -$20.00K
Free Cash Flow $3.720M -$3.180M
YoY Change -216.98% -46.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16246000
CY2018Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8072000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2991000
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2018Q2 us-gaap Assets
Assets
79879000
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5576000
CY2017Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
14600000
CY2018Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
15721000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
42906000
CY2018Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
686000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31876000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2017Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-64000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1017000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
15645000
us-gaap Operating Expenses
OperatingExpenses
42320000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3599000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10444000
CY2018Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-424000
CY2017Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1691000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-3119000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-42000
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-188000
CY2018Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-8768000
CY2017Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
1067000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-7447000
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14443000
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4411000
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-376000
CY2018Q2 us-gaap Profit Loss
ProfitLoss
-14062000
CY2017Q2 us-gaap Profit Loss
ProfitLoss
-4035000
us-gaap Profit Loss
ProfitLoss
-9644000
CY2017Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-67000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
23032000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5209000
CY2017Q4 us-gaap Assets
Assets
83565000
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3480000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3391000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5013000
CY2018Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4703000
CY2017Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3735000
CY2018Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
39000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
39000
CY2018Q2 cdna Business Acquisition Deferred Payment Consideration With Interest Accretion Current Portion
BusinessAcquisitionDeferredPaymentConsiderationWithInterestAccretionCurrentPortion
378000
CY2017Q4 cdna Business Acquisition Deferred Payment Consideration With Interest Accretion Current Portion
BusinessAcquisitionDeferredPaymentConsiderationWithInterestAccretionCurrentPortion
407000
CY2018Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36346124
CY2018Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
16800000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17823000
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12046000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3496000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
9579000
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1593000
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2360000
CY2018Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
34760000
CY2018Q2 us-gaap Goodwill
Goodwill
12005000
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
177000
CY2018Q2 us-gaap Inventory Net
InventoryNet
4666000
CY2018Q2 us-gaap Assets Current
AssetsCurrent
30577000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-25000
us-gaap Net Income Loss
NetIncomeLoss
-23031000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2851000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32599032
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-114000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23861000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10303000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-805000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-659000
us-gaap Profit Loss
ProfitLoss
-23056000
us-gaap Net Income Loss
NetIncomeLoss
-9530000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32599032
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1958000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23630000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10634000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6492000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21378321
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-285000
us-gaap Operating Expenses
OperatingExpenses
35773000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12143000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2481000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-874000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
5195000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21378321
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
934000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-25000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24793000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1762000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-24818000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8710000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-124000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0
CY2017Q4 us-gaap Minority Interest
MinorityInterest
180000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28825019
CY2018Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
13337000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28825019
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
79879000
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35975493
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2345000
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4108000
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-288120000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-268022000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83565000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
28952000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-6134000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q2 us-gaap Minority Interest
MinorityInterest
0
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
4933000
CY2018Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
28952000
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35975493
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5954000
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
14176000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
913000
CY2018Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
711000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
730000
CY2018Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
3693000
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
321144000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
264204000
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10903000
us-gaap Share Based Compensation
ShareBasedCompensation
886000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
461000
us-gaap Share Based Compensation
ShareBasedCompensation
3217000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
94000
CY2017Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2018Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
873000
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-381000
CY2018Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-14062000
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35549837
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35549837
CY2018Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1625000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-15687000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2132000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
32000
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
11349000
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-3968000
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21412480
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21412480
CY2017Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
670000
CY2017Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-3365000
CY2017Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-72000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15687000
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3293000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8586000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2025000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1821000
us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
189000
us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
170000
cdna Loss On Conversion Of Debt To Shares Of Common Stock
LossOnConversionOfDebtToSharesOfCommonStock
2806000
cdna Loss On Conversion Of Debt To Shares Of Common Stock
LossOnConversionOfDebtToSharesOfCommonStock
0
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1769000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2280000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
152000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-333000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-252000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
296000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
189000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
195000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
422000
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
686000
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
-486000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
92000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-710000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-19000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
892000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
542000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6404000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9937000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6355000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-94000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
14282000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
24002000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
44000
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
12871000
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-677000
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
176000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
524000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
142000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
179000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2758000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11351000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-50000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-64000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10051000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1256000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26474000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17401000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16423000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18657000
cdna Business Acquisition Deferred Payment Consideration
BusinessAcquisitionDeferredPaymentConsideration
0
cdna Business Acquisition Deferred Payment Consideration
BusinessAcquisitionDeferredPaymentConsideration
1064000
cdna Contingent Consideration Deferred Payment In Shares
ContingentConsiderationDeferredPaymentInShares
2689000
cdna Contingent Consideration Deferred Payment In Shares
ContingentConsiderationDeferredPaymentInShares
0
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
177000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
9579000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Use of Estimates</font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes.&nbsp;&nbsp;On an ongoing basis, management evaluates its estimates, including those related to (i)&#160;variable transaction price consideration related to contracts with customers, (ii)&#160;the determination of the accruals for clinical studies, (iii)&#160;the fair value of assets and liabilities acquired in business combinations, including contingent consideration, (iv)&#160;inventory valuation, (v) the valuation of common stock warrant liability, (vi) the fair value of embedded derivatives, (vii) measurement of stock-based compensation expense, (viii)&#160;the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (ix)&#160;any impairment of long-lived assets, including in-process technology and goodwill, and (x)&#160;legal contingencies.&nbsp;&nbsp;Actual results could differ from those estimates.</p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Concentrations of Credit Risk and Other Risks and Uncertainties</font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the six months ended June 30, 2018 and 2017, approximately 45% and 28%, respectively, of total revenue was derived from Medicare.<font style="color:#000000;"> No other payers or customers represented more than 10% of total revenue for these periods.</font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At June 30, 2018 and December 31, 2017, approximately 24% and 16%, respectively, of accounts receivable was due from Medicare.&nbsp;&nbsp;No other payer or customer represented more than 10% of accounts receivable on either June 30, 2018 or December&#160;31, 2017. </p></div>
us-gaap Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Product Revenue</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue is recognized from the sale of products to end-users, distributors and strategic partners when all revenue recognition criteria are satisfied.&nbsp;&nbsp;The Company generally has a contract or a purchase order from a customer with the specified required terms of order, including the number of products ordered. Transaction prices are determinable and products are delivered and risk of loss passed to the customer upon either shipping or delivery, as per the terms of the agreement. There are no further performance obligations related to a contract and revenue is recognized at the point of delivery consistent with the terms of the contract or purchase order.</p></div>
us-gaap Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License and Other Revenue</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenue from license agreements.&nbsp;&nbsp;License agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized.&nbsp;&nbsp;The Company&#8217;s performance obligations under the agreements may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees.&nbsp;&nbsp;The Company makes judgments to determine if performance obligations are distinct or should be combined and the transaction price allocated to each performance obligation, which affect the periods over which revenue is recognized.&nbsp;&nbsp;The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis. The Company constrains variable consideration, such as milestones, if it is probable that a significant portion of revenue would be reversed. The Company&#8217;s deferred revenue relates to one performance obligation, which should be recognized over time.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not recognize any revenue connected with milestones during the three or six months ended June 30, 2018 or 2017.</p></div>
CY2018Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
43077000
CY2018Q2 cdna Intangible Assets Excluding Goodwill Accumulated Amortization
IntangibleAssetsExcludingGoodwillAccumulatedAmortization
5665000
us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0
CY2017Q2 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0
CY2018Q2 cdna Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
2652000
us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35549837
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21412480
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32599032
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21378321
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2018Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
29938000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2018Q2 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
13300000
CY2018Q2 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6786451
CY2017Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13082072
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6786451
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13082072
cdna Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2017 cdna Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
us-gaap New Date Of Annual Goodwill Impairment Test
NewDateOfAnnualGoodwillImpairmentTest
On January 1, 2017, the Company adopted ASU 2017-04, which eliminated the Step 2 requirement of the goodwill impairment test. Instead, the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. The Company determined that the decrease in its market capitalization in the first quarter of 2017 constituted an indicator of impairment and therefore a goodwill impairment test was completed as of March 31, 2017.
CY2018Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
38255000
CY2018Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5665000
CY2018Q2 cdna Intangible Assets Excluding Goodwill Foreign Currency Translation Gain Loss
IntangibleAssetsExcludingGoodwillForeignCurrencyTranslationGainLoss
2652000
CY2017Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
37875000
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4166000
CY2017Q4 cdna Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
570000
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
33139000
CY2018Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000
CY2017Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1200000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1200000
CY2018Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1482000
CY2018Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2960000
CY2018Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2960000
CY2018Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2813000
CY2018Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2813000
CY2018Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
986000
CY2018Q2 cdna Accrued Software Implementation Costs
AccruedSoftwareImplementationCosts
50000
CY2017Q4 cdna Accrued Software Implementation Costs
AccruedSoftwareImplementationCosts
94000
CY2018Q2 us-gaap Interest Payable Current
InterestPayableCurrent
37000
CY2018Q2 us-gaap Payments For Royalties
PaymentsForRoyalties
200000
us-gaap Payments For Royalties
PaymentsForRoyalties
200000
CY2018Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
2813000
CY2018Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
14097000
CY2018Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1379000
CY2017Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2569000
CY2018Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1548000
CY2017Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1471000
CY2018Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1739000
CY2017Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1489000
CY2018Q2 cdna Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
1580000
CY2017Q4 cdna Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
1115000
CY2018Q2 cdna Accrued Sample Processing Fees
AccruedSampleProcessingFees
614000
CY2017Q4 cdna Accrued Sample Processing Fees
AccruedSampleProcessingFees
633000
CY2018Q2 cdna Accrued Shares Withheld In Lieu Of Taxes
AccruedSharesWithheldInLieuOfTaxes
557000
CY2017Q4 cdna Accrued Shares Withheld In Lieu Of Taxes
AccruedSharesWithheldInLieuOfTaxes
0
CY2018Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
419000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
419000
CY2018Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
398000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
475000
CY2018Q2 cdna Customer Overpayments And Refunds Due
CustomerOverpaymentsAndRefundsDue
259000
CY2017Q4 cdna Customer Overpayments And Refunds Due
CustomerOverpaymentsAndRefundsDue
270000
CY2018Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
139000
CY2017Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
13000
CY2018Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
159000
CY2017Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
0
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
81000
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
491000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
635000
cdna Leases Expiration Period
LeasesExpirationPeriod
2020
CY2018Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2017Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
900000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
900000
CY2018Q2 us-gaap Capital Leases Future Minimum Payments Remainder Of Fiscal Year
CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear
85000
CY2018Q2 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
162000
CY2018Q2 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
157000
CY2018Q2 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
45000
CY2018Q2 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
0
CY2018Q2 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
449000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1111000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2133000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2046000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
10000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
7000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
5307000
cdna Description Of Agreement Expected Expiration Year
DescriptionOfAgreementExpectedExpirationYear
The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014.
CY2013Q2 cdna Upfront Payment In Cash
UpfrontPaymentInCash
387500
CY2013Q2 cdna Upfront Payment In Cash
UpfrontPaymentInCash
408000
CY2018Q2 cdna Revenues And Royalties Recognized
RevenuesAndRoyaltiesRecognized
10000
CY2017Q2 cdna Revenues And Royalties Recognized
RevenuesAndRoyaltiesRecognized
10000
cdna Revenues And Royalties Recognized
RevenuesAndRoyaltiesRecognized
19000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
674093
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1941473
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Assumed From Acquisitions In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedFromAcquisitionsInPeriod
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
167379
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2561458
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.21
CY2018Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
6191000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
13591000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2512000
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
495000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3217000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
886000
cdna Revenues And Royalties Recognized
RevenuesAndRoyaltiesRecognized
19000
CY2018Q2 cdna Royalty Revenue Receivable
RoyaltyRevenueReceivable
0
CY2017Q4 cdna Royalty Revenue Receivable
RoyaltyRevenueReceivable
0
CY2018Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1663000
CY2017Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
4600000
CY2018Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
0
CY2017Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
300000
CY2018Q2 cdna Long Term Debt Maturities Repayments In Year Four
LongTermDebtMaturitiesRepaymentsInYearFour
2025000
CY2018Q2 cdna Long Term Debt Maturities Repayments In Year Five
LongTermDebtMaturitiesRepaymentsInYearFive
2700000
CY2018Q2 cdna Long Term Debt Maturities Repayments After Year Five
LongTermDebtMaturitiesRepaymentsAfterYearFive
10275000
CY2018Q2 cdna Long Term Debt Maturities Repayments
LongTermDebtMaturitiesRepayments
15000000
CY2018Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2018Q2 cdna Purchase Of Common Stock Warrants Exercised
PurchaseOfCommonStockWarrantsExercised
445000
cdna Purchase Of Common Stock Warrants Exercised
PurchaseOfCommonStockWarrantsExercised
468000
CY2018Q2 cdna Estimated Fair Value Of Warrant Liability Remeasurement Income Expense
EstimatedFairValueOfWarrantLiabilityRemeasurementIncomeExpense
5200000
cdna Estimated Fair Value Of Warrant Liability Remeasurement Income Expense
EstimatedFairValueOfWarrantLiabilityRemeasurementIncomeExpense
5400000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
156429
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
1957075
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
13050
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
0
cdna Share Based Compensation Arrangement By Share Based Payment Award Repurchases Of Common Stock Under Employee Incentive Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans
67656
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
809634
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
20453
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1817
cdna Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Exercised Price Shares Reserved
ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageExercisedPriceSharesReserved
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.05
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.07
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.78
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
3.55
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
900000
CY2018Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber
991627
CY2018Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
1360609
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2352236
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
6.57
CY2018Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
7.83
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm
P6Y8M23D
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
P7Y6M14D
CY2018Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue
7400000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
CY2018Q2 cdna Intersegment Sales
IntersegmentSales
0
cdna Intersegment Sales
IntersegmentSales
0
CY2017Q2 cdna Intersegment Sales
IntersegmentSales
0
cdna Intersegment Sales
IntersegmentSales
0
CY2017Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
887000

Files In Submission

Name View Source Status
0001564590-18-021123-index-headers.html Edgar Link pending
0001564590-18-021123-index.html Edgar Link pending
0001564590-18-021123.txt Edgar Link pending
0001564590-18-021123-xbrl.zip Edgar Link pending
cdna-10q_20180630.htm Edgar Link pending
cdna-20180630.xml Edgar Link completed
cdna-20180630.xsd Edgar Link pending
cdna-20180630_cal.xml Edgar Link unprocessable
cdna-20180630_def.xml Edgar Link unprocessable
cdna-20180630_lab.xml Edgar Link unprocessable
cdna-20180630_pre.xml Edgar Link unprocessable
cdna-ex101_331.htm Edgar Link pending
cdna-ex102_75.htm Edgar Link pending
cdna-ex103_618.htm Edgar Link pending
cdna-ex311_6.htm Edgar Link pending
cdna-ex312_7.htm Edgar Link pending
cdna-ex321_9.htm Edgar Link pending
cdna-ex412_332.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending